Meridian Mining plc awarded deferred share units (DSUs) to two newly appointed Non-Executive Directors, Carlos Vilhena and Felipe Holzhacker Alves, on September 10, 2026. Each director received 44,118 DSUs valued at CAD75,000 based on the last equity issue price of CAD1.70. These awards are part of the company's Omnibus Incentive Plan and will vest monthly over a year, payable upon the directors' departure from the board. This move fulfills commitments made before their election and the company's London Stock Exchange listing, with shareholder consultation involved.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
